Bryan, Garnier & Co's News

Genmab: Daratumumab is becoming an increasingly critical asset for JNJ

BUY-Top Picks, Fair Value DKK1170 (+39%)
News published on
January Friday 29, 2016


For more information, please contact marketing@bryangarnier.com